Kenvue (KVUE): Forward P/S Multiple
Kenvue Inc. (KVUE) dominates the consumer health segment with global brands Tylenol and Listerine. The forward price-to-sales ratio visualizes these positions, where the value 1.70 captures the metric level. Such stability in staple goods sales guarantees predictable income. Consequently, a powerful ecosystem of consumer habits has formed, although talc-related litigation remains a constraining factor.
Metric breakdowns and analytics for Kenvue Health (KVUE)
- market price and analyst price targets:
- stock exchange capitalization data:
- issuer book value statistics:
- debt and liquidity data:
- business earnings and investment ratios data:
KVUE - Company Profit|Projected Future Earnings Kenvue Inc.|KVUE - Price to Earnings Ratio|Projected Price to Earnings Kenvue Corp|KVUE - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kenvue Health|KVUE - Operating profit EBITDA|Net earnings per share for the last 12 months Kenvue|KVUE - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months kenvue.com|KVUE - Earnings growth in current year|Earnings growth forecast for next year Kenvue Inc.
- sales and revenue indicators:
Initial company analysis:Kenvue (KVUE)
Stable demand for Kenvue Inc. (KVUE) consumer staples ensures high cash flow predictability. The forward P/S metric relates current market capitalization to expected sales volume, allowing investors to determine the extent of overpayment for future earnings. Analyzing the trend of this metric helps investors recognize the risk of asset overheating in a timely manner and select the optimal entry point for long-term holding.
Key competitors
Price-to-Projected Revenue Ratio Haleon HLN|Forward P/S Multiple Verona Pharma PLC VRNA|Jyong Biotech Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ligand Corp|Amneal Pharmaceuticals (AMRX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue PRGO|Forward Price-to-Revenue Multiple ALVO|Price-to-Projected Revenue Ratio LQDA|Forward Price-to-Revenue Multiple GLPG (Galapagos Genomics)|Forward P/S Multiple ANI Pharmaceuticals Corp (ANIP)|Forward P/S Multiple MNKD (MannKind Corporation)|amphastar.com (AMPH) - Market Cap to Future Revenue Ratio|PCRX: Forward Price-to-Revenue Multiple|Forward Price to Sales SPRY (ARS Pharmaceuticals Inc)|TBPH: Forward P/S Multiple|AQST - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio scPharmaceuticals, Inc.|Market Cap to Projected Revenue TECX (Tectonic)|Forward P/S Multiple TNXP|Forward Price-to-Revenue Multiple sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio BioHarvest Sciences Inc (BHST)|EXOZ - Price-to-Projected Revenue Ratio|ORMP - Forward P/S Multiple|ENTX (enterabio.com) - Forward Price-to-Revenue Multiple|HYFT (MindWalk Holdings, Inc.) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ABVC|Forward P/S Multiple Cumberland Corp|Forward P/S Multiple QNTM|FGEN - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Telomir Pharmaceuticals, Inc. TELO|RANI (Rani Therapeutics Holdings) - Future Price to Revenue|Synergy CHC Corporation - Forward P/S Multiple|Forward Price to Sales RLYB (Rallybio Corporation)|LEXX: Forward P/S Multiple|pulmatrix.com (PULM) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Pheton Holdings Limited|APM: Forward Price to Sales|Price-to-Projected Revenue Ratio Lyra Therapeutics, Inc (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical, Inc. IBO|Forward P/S Multiple TNFA (TNF Pharmaceuticals, Inc.)|Forward P/S Multiple cbdMD Inc. YCBD|PRFX: Forward Price-to-Revenue Multiple|Forward Price to Sales CYTO (Altamira Therapeutics)|Lipella (LIPO) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio OptiNose Corp (OPTN)|Forward Price-to-Revenue Multiple PIRS|PROC (procapsgroup.com) - Price to Expected Revenue Ratio|Forward P/S Multiple PTPI|QLI (Qilian International Holding Group) - Forward Price to Sales|Forward P/S Multiple SLRN (ACELYRIN, Inc.)|TFF Pharmaceuticals, Inc (TFFP) - Market Cap to Future Revenue Ratio
